Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Mostly true True only under certain conditions Certainty of evidence: low provisional C-CHM-07

At the end of life, chemotherapy often does not help, and early palliative care improves quality of life and even survival (Temel 2010).

Safety note: These findings concern advanced, incurable cancer near the end of life. They do not apply to curative or life-prolonging treatment. Palliative care is given alongside cancer treatment, not instead of it. Decisions about stopping treatment should be made with the oncology team, ideally with early palliative care.
In short: Mostly true for advanced, incurable cancer: early palliative care alongside cancer treatment improves quality of life, and chemotherapy in the last weeks of life often does not help; whether palliative care also prolongs survival is uncertain, and none of this applies to curative treatment.
Conclusion: Mostly true for advanced, incurable cancer near the end of life: early palliative care alongside treatment improves quality of life and chemotherapy in the last weeks often does not help; a survival benefit of palliative care is uncertain, and none of this applies to curative treatment.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

أثبت تيميل (NEJM 2010) أن الرعاية التلطيفية المبكرة لسرطان الرئة المنتشر تحسّن جودة الحياة وتُطيل البقيا (11.6 شهراً مقابل 8.9) رغم تخفيف العلاج الكيماوي

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

At the end of life, chemotherapy often does not help, and early palliative care improves quality of life and even survival (Temel 2010).

Origin

Source status
Archive editors
Attribution
Archive editors (rule page summary/narrative)
Origin
https://eltayebat.com/rule/chemo-radiation/
Attribution uncertainty
Written by archive operators; not attributed to Elawady.
Population concerned

Patients with metastatic or end-stage cancer

Geographic restriction by Elawady

none found

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

Early palliative care improves QoL and prolongs survival despite less aggressive chemotherapy; chemo near death does not improve quality of death.

2. What is demonstrably correct?

Temel's RCT: better QoL (FACT-L 98.0 vs 91.5), fewer depressive symptoms, less aggressive end-of-life care, median survival 11.6 vs 8.9 months (A-CHM-16). Chemotherapy near death did not improve, and in fit patients worsened, quality of death (A-CHM-17); end-of-life overuse is a recognised issue (A-CHM-18).

3. What is wrong or exaggerated?

'Proved ... prolonged survival' overstates the evidence: in Temel's trial survival was a secondary endpoint, and the Cochrane review found the survival effect of early palliative care uncertain (HR 0.85, 95% CI 0.56-1.28; very low certainty; I-CHM-104), while another meta-analysis found a benefit (I-CHM-128). The abstract reports less aggressive end-of-life care, not generally less chemotherapy; both arms received standard oncologic care, and guidelines recommend palliative care concurrent with active treatment (I-CHM-105). In advanced disease, chemotherapy still prolongs life for fit patients (non-small-cell lung cancer: 1-year survival 20% to 29%; I-CHM-103). These data concern metastatic or end-stage disease and do not apply to curative treatment.

4. What remains unclear?

Mechanism of the survival effect.

5. Which studies support it?

A-CHM-16, A-CHM-17, A-CHM-18; I-CHM-128 (1-year survival 56% vs 42% with outpatient specialty palliative care in three high-quality RCTs); I-CHM-104 (quality of life SMD 0.27, low certainty).

6. Which studies contradict it?

Survival part: I-CHM-104 (Cochrane: survival effect uncertain). Scope: I-CHM-103 (chemotherapy prolongs survival in advanced NSCLC for fit patients); for curative settings I-CHM-01, I-CHM-02. I-CHM-105 (ASCO: palliative care concurrent with, not instead of, active treatment).

7. What applies to Germany and Europe?

Early palliative care integration is recommended in European oncology (not audited here).

8. What is known about Egypt?

Palliative-care availability may be limited (no data reviewed).

9. What practical conclusion is appropriate?

Ask early for palliative/supportive care alongside cancer treatment; discuss goals of care near the end of life.

Assessment details

Rationale for certainty of evidence

One RCT (Temel; survival a secondary endpoint) and observational data on end-of-life chemotherapy. The Cochrane review of early palliative care (I-CHM-104) rates the quality-of-life benefit as low-certainty and the survival effect as very low-certainty (HR 0.85, 0.56-1.28); a smaller meta-analysis of three high-quality trials found higher 1-year survival (56% vs 42%; I-CHM-128). The syntheses overlap and disagree on survival.

Source quality

Correct numbers; overstated wording.

Regional transferability

Moderate.

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

True only under certain conditions – The claim holds only for certain doses, groups of people, preparations or circumstances.

Research question: In patients with advanced incurable cancer, does chemotherapy near the end of life often fail to help, and does early palliative care improve quality of life and survival?

Research question in detail (PICO)
Population
Adults with advanced/metastatic cancer
Intervention or exposure
Early palliative care; chemotherapy near death
Comparison
Usual oncology care; no chemotherapy
Geographic scope
universal; service availability varies
Outcomes
  • Quality of life
  • Survival
  • Quality of death

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Early palliative care, given alongside oncology care, improves quality of life (small effect); a survival benefit is possible but uncertain. Chemotherapy in the last weeks of life, especially in frail patients, often does not help; earlier in advanced disease it prolongs life for fit patients.

Why some studies weigh more

Cochrane (GRADE) weighs most for palliative care; IPD meta-analysis for chemotherapy benefit; overlapping syntheses not counted twice.

Is a causal relationship established? Probable Randomised evidence for quality of life; survival evidence inconsistent.

Remaining uncertainty

Whether early palliative care prolongs survival; how to identify patients for whom chemotherapy no longer helps.

Justified conclusion

Mostly true within its scope (end of life, advanced disease); the 'even survival' part is uncertain; none of it applies to curative treatment.

Why do studies seem to disagree?

Hoerger (survival benefit) vs Haun (uncertain): different trial selection (high-quality outpatient specialty trials vs all early palliative care trials), fixed time-point vs hazard ratio; overlapping trial pool, so not independent.

Does this depend on the country?
General biological effects
Universal clinical evidence; palliative-care availability differs between countries.
Eating habits
Not relevant.
Origin of the food
Not relevant.
Contaminants
Not relevant.
National production conditions
Not relevant.
Legal rules
Not relevant.
Actual monitoring data
Palliative-care service availability in Egypt was not reviewed.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • Proportional-hazards consistency – 0.20^0.77 = 0.29 matches reported 1-year survival; NNT about 11 recalculated
  • Precision of survival HR – HR 0.85 (0.56-1.28) symmetric on log scale, very imprecise recalculated
  • Absolute effect; overlap – 1-year survival +14 points (NNT about 7); same small pool of trials as I-CHM-104, so not an independent confirmation recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Survival with early palliative care
Starting level
high (randomised trials)
Reasons for downgrading
  • imprecision
  • inconsistency
  • risk of bias (unblinded)
Result
low

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked
  • ASCO: Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update (Ferrell BR et al., J Clin Oncol 2017; I-CHM-105) (2017) · Original publication
    Patients with advanced cancer should receive dedicated palliative care services early in the disease course, concurrent with active treatment (read from the PubMed abstract; publisher page returned HTTP 403).
  • WHO: Cancer - fact sheet (2026 (page fetched 2026-10-26)) · Original publication
    Many cancers can be cured if detected early and treated effectively; treatment usually includes surgery, radiotherapy and/or systemic therapy; some cancers such as testicular seminoma and childhood leukaemias and lymphomas have high cure rates with appropriate treatment even when spread; palliative care relieves symptoms in advanced cancer.
Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026TITLE:"early palliative care" AND TITLE:"advanced cancer" AND JOURNAL:"Cochrane Database Syst Rev"both directions1
Europe PMC26 October 2026TITLE:"palliative care" AND TITLE:"survival" AND TITLE:"meta-analysis" AND (TITLE:"early" OR TITLE:"specialist") AND PUB_YEAR:[2019 TO 2026]supporting evidence0
PubMed26 October 2026("early palliative care"[ti] OR "palliative care"[ti]) AND (survival[ti]) AND (randomized[ti] OR randomised[ti] OR trial[ti]) AND (cancer[ti])supporting evidence1
Europe PMC26 October 2026TITLE:"chemotherapy" AND (TITLE:"end of life" OR TITLE:"last days" OR TITLE:"near death" OR TITLE:"last 30 days") AND PUB_YEAR:[2014 TO 2026] AND (TITLE:"survival" OR TITLE:"quality")supporting evidence6
Europe PMC26 October 2026TITLE:"chemotherapy" AND TITLE:"supportive care" AND TITLE:"non-small-cell lung cancer" AND (TITLE:"meta-analysis" OR TITLE:"individual patient")contradicting evidence3
Europe PMC26 October 2026TITLE:"Integration of Palliative Care Into Standard Oncology Care"guidelines7
PubMed26 October 2026"Integration of Palliative Care Into Standard Oncology Care"[ti] AND Ferrell BR[au]guidelines0

Open questions

Survival effect of early palliative care in larger trials; availability of palliative care in Egypt.

How deeply was this checked?

7 linked studies: 1 checked in full text (1 of them with a structured risk-of-bias assessment), 6 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Mostly true (moderate)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Verdict changed: Mostly true (moderate) → Mostly true (low)
    Verdict unchanged. Certainty lowered to low: the Cochrane review rates the quality-of-life evidence as low and the survival evidence as very low certainty, and two overlapping meta-analyses disagree on survival.
    New sources: I-CHM-104 I-CHM-128 I-CHM-103 I-CHM-105

In plain language

In advanced cancer, adding specialised palliative care early, alongside cancer treatment, improves quality of life a little and helps with symptoms. Some studies suggest patients also live longer, but this is not certain. Chemotherapy in the last weeks of life often does not help. Earlier in advanced disease, chemotherapy can still give fit patients more time. None of this means that chemotherapy is useless in earlier, curable stages.

Studies on this claim

Studies supporting the claim (4)

  • Early palliative care helps patients with advanced lung cancer

    Temel JS et al.. N Engl J Med 2010 · PMID 20818875 · DOI 10.1056/NEJMoa1000678
    Randomised controlled trialcited by the Tayebat archiveabstract checked★ key study

    Better quality of life, less depression, and longer median survival (11.6 vs 8.9 months) when added to cancer care.

    Early palliative care benefit

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Test early palliative care.

    How was the study done?

    RCT.

    How many people, animals or samples were studied?

    151 patients.

    What was actually found?

    QoL and mood better; survival longer.

    How large was the observed effect?

    +2.7 months median (11.6 vs 8.9 months; calculated).

    What do the results mean in everyday life?

    Ask early for palliative/supportive care.

    What are the study's limitations?

    Small single-centre trial.

    What does it say about Elawady's specific claim?

    Supports palliative care, not refusal of oncology.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    That chemotherapy is useless.

    Scientific details →

  • Chemotherapy in the last months of life did not improve quality of dying

    Prigerson HG et al.. JAMA Oncol 2015 · PMID 26203912 · DOI 10.1001/jamaoncol.2015.2378
    Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment

    In patients still fit, chemotherapy near death was linked to worse quality of the last week.

    End-of-life chemo

    Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Assess end-of-life chemo.

    How was the study done?

    Prospective cohort.

    How many people, animals or samples were studied?

    312.

    What was actually found?

    No survival or QoD benefit.

    How large was the observed effect?

    OR 0.35 (ECOG 1).

    What do the results mean in everyday life?

    Discuss goals of care near end of life.

    What are the study's limitations?

    Not randomised; chemotherapy users were younger and fitter; only patients who died were analysed; no dose data; caregiver-rated outcome.

    What does it say about Elawady's specific claim?

    Supports for end-stage only.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    That chemotherapy is harmful in curative, adjuvant or first-line settings; that chemotherapy never prolongs life in advanced cancer.

    Scientific details →

  • Too much chemotherapy close to death is a recognised problem

    Earle CC et al.. J Clin Oncol 2008 · PMID 18688053 · DOI 10.1200/JCO.2007.15.8253
    Narrative reviewcited by the Tayebat archiveabstract checked

    Review of chemotherapy overuse and late hospice referral in the USA.

    End-of-life overuse

    Does the study support the specific claim? Yes · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Review end-of-life care.

    How was the study done?

    Narrative.

    What was actually found?

    Overuse trends.

    What do the results mean in everyday life?

    Plan end-of-life care early.

    What are the study's limitations?

    Narrative.

    What does it say about Elawady's specific claim?

    Supports end-of-life point only.

    Do the results apply to Germany and Europe?

    Low-moderate.

    What can explicitly not be concluded from this study?

    Curative-setting conclusions.

    Scientific details →

  • Palliative care and survival: a meta-analysis

    Hoerger M et al.. Ann Behav Med 2019 · PMID 30265282 · DOI 10.1093/abm/kay077
    Meta-analysisindependent cross-checkabstract checked

    In three good-quality trials, patients with palliative care alongside cancer treatment were more often alive after one year (56% vs 42%).

    Specialty palliative care (concurrent with oncology care) associated with higher 1-year survival in 3 high-quality RCTs.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Measure palliative care effect on survival

    How was the study done?

    Meta-analysis of RCTs

    How many people, animals or samples were studied?

    646 patients for survival

    What was actually found?

    Longer survival, better quality of life

    How large was the observed effect?

    56% vs 42% alive at 1 year

    What do the results mean in everyday life?

    Palliative care added to treatment may help people live longer and better

    What are the study's limitations?

    Few trials; conflicts with Cochrane

    What does it say about Elawady's specific claim?

    Partly supports the claim

    Do the results apply to Germany and Europe?

    Moderate

    What can explicitly not be concluded from this study?

    Does not mean stopping cancer treatment

    Scientific details →

Studies contradicting or limiting the claim (2)

  • Cochrane review: early palliative care in advanced cancer

    Haun MW et al.. Cochrane Database Syst Rev 2017 · PMID 28603881 · DOI 10.1002/14651858.CD011129.pub2
    Meta-analysisindependent cross-checkabstract checked★ key study

    Early palliative care slightly improved quality of life and symptoms; any survival effect is uncertain.

    Quality-of-life benefit confirmed (small); the 'even survival' part is not confirmed (HR 0.85, 0.56-1.28, very low certainty).

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Summarise trials of early palliative care

    How was the study done?

    Cochrane systematic review

    How many people, animals or samples were studied?

    7 trials, 1614 adults

    What was actually found?

    Small quality-of-life gain; survival unclear

    How large was the observed effect?

    QoL SMD 0.27; survival HR 0.85 (0.56-1.28)

    What do the results mean in everyday life?

    Palliative care helps people feel better; it is given alongside, not instead of, cancer treatment

    What are the study's limitations?

    Few, unblinded trials

    What does it say about Elawady's specific claim?

    Supports the quality-of-life part; does not confirm longer survival

    Do the results apply to Germany and Europe?

    High

    What can explicitly not be concluded from this study?

    Cannot show that palliative care replaces anticancer treatment

    Scientific details →

  • Chemotherapy vs supportive care alone in advanced lung cancer

    NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162
    Meta-analysisindependent cross-checkabstract checked★ key study

    Chemotherapy raised 1-year survival from 20% to 29%.

    Chemotherapy prolongs life in advanced disease when patients are fit; 'often does not help' applies near death, not to advanced cancer in general.

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Measure survival benefit of chemotherapy in advanced lung cancer

    How was the study done?

    IPD meta-analysis of randomised trials

    How many people, animals or samples were studied?

    2714 patients in 16 trials

    What was actually found?

    23% lower risk of death

    How large was the observed effect?

    HR 0.77; 1-year survival 20% -> 29%

    What do the results mean in everyday life?

    About 1 in 11 treated patients is alive at 1 year because of chemotherapy

    What are the study's limitations?

    Older drugs; modest absolute gain

    What does it say about Elawady's specific claim?

    Contradicts 'oncology only buys time' as meaningless and 'chemo often does not help' in fit patients

    Do the results apply to Germany and Europe?

    High

    What can explicitly not be concluded from this study?

    Does not show benefit for frail patients in their last weeks

    Scientific details →

Studies with mixed or unclear results (1)

  • ASCO guideline: palliative care alongside cancer treatment

    Ferrell BR et al.. J Clin Oncol 2017 · PMID 28034065 · DOI 10.1200/JCO.2016.70.1474
    Guideline / position statementindependent cross-checkabstract checked

    Patients with advanced cancer should get palliative care early, together with active treatment.

    Supports early palliative care; specifies it is concurrent with active treatment, which limits any reading as a reason to stop treatment.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Give guidance on palliative care

    How was the study done?

    Guideline based on a systematic review

    How many people, animals or samples were studied?

    Trials 2010-2016

    What was actually found?

    Early, concurrent palliative care recommended

    How large was the observed effect?

    Not applicable

    What do the results mean in everyday life?

    Palliative care is an addition to cancer treatment

    What are the study's limitations?

    US-based expert panel

    What does it say about Elawady's specific claim?

    Supports palliative care; contradicts using it as a reason to refuse treatment

    Do the results apply to Germany and Europe?

    Moderate

    What can explicitly not be concluded from this study?

    Not a trial

    Scientific details →

Regional context

Germany / EU

Early palliative care integration is recommended in European oncology (not audited here).

Egypt

Palliative-care availability may be limited (no data reviewed).

What applies in my country?

General scientific assessment

Mostly true Mostly true for advanced, incurable cancer near the end of life: early palliative care alongside treatment improves quality of life and chemotherapy in the last weeks often does not help; a survival benefit of palliative care is uncertain, and none of this applies to curative treatment.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Early palliative care for patients with metastatic non-small-cell lung cancer.. Temel JS et al.. N Engl J Med 2010 · PMID 20818875 · DOI 10.1056/NEJMoa1000678
  2. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.. Prigerson HG et al.. JAMA Oncol 2015 · PMID 26203912 · DOI 10.1001/jamaoncol.2015.2378
  3. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?. Earle CC et al.. J Clin Oncol 2008 · PMID 18688053 · DOI 10.1200/JCO.2007.15.8253
  4. Impact of Interdisciplinary Outpatient Specialty Palliative Care on Survival and Quality of Life in Adults With Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials.. Hoerger M et al.. Ann Behav Med 2019 · PMID 30265282 · DOI 10.1093/abm/kay077
  5. Early palliative care for adults with advanced cancer.. Haun MW et al.. Cochrane Database Syst Rev 2017 · PMID 28603881 · DOI 10.1002/14651858.CD011129.pub2
  6. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.. NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162
  7. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update.. Ferrell BR et al.. J Clin Oncol 2017 · PMID 28034065 · DOI 10.1200/JCO.2016.70.1474

← Back to overview